NCT05036668

Study of Efficacy and Safety of ABO809 in Healthy Participants

An Open Label Cryptosporidium Controlled Human Infection Model (CHIM) to Assess the Efficacy and Safety of ABO809 in Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

The purpose of this Phase I controlled human infection model (CHIM) study was to determine if oral administration of a good manufacturing practice (GMP) supply of Cryptosporidium parvum oocysts (ABO809) to healthy volunteers resulted in a Cryptosporidium infection and diarrheal illness. The study measured fecal oocysts (parasitological endpoint) as well as diarrhea and associated signs and symptoms (clinical endpoint).

Detailed description

This study was funded by the Wellcome Trust. This Phase 1 Cryptosporidium controlled human infection model (CHIM) study employed a single-center, open-label design to characterize the incidence of infection and associated symptoms following the administration of single doses of Cryptosporidium parvum oocysts (CE). Healthy volunteers were enrolled in cohorts of approximately 10 participants who received ABO809 on the same day (Day 1). The study consisted of three sequential cohorts which were dosed one after the other for a total of 30 participants. A dose level group received the same ABO809 dose and could be comprised of multiple cohorts. The first dose level group started with a cohort of 10 participants who received ABO809 at a dose of 1x10\^4 oocysts. The study continued to enroll participants in the same dose level group if the desired incidences of infection and diarrheal illness were observed, up to a total of approximately 30 participants. If the desired incidences of infection and diarrheal illness were not observed, a new dose level group, receiving ABO809 at a dose of 1x10\^6 oocysts, could be initiated. If needed to optimize the model, intermediate ABO809 doses could be evaluated.

Conditions

• Cryptosporidium Infection, Cryptosporidiosis

Interventions

Type	Name	Description
BIOLOGICAL	Cryptosporidium parvum oocysts (ABO809)	ABO809 3x10\^6 CE/3mL concentrate for oral suspension, single dose at Day 1

Timeline

• Start date: 2022-04-07
• Primary completion: 2022-11-07
• Completion: 2022-12-27
• First posted: 2021-09-05
• Last updated: 2024-10-02
• Results posted: 2024-10-02

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study